Therapeutics targeted against COVID-2019 infections (originated in Wuhan, China) and other infectious diseases [Infections in development table], are being jointly developed by Q BioMed and Mannin Research (research partner of Q BioMed). The development is utilising Mannin's lead research platform, which targets the activation of the Angiopoietin-Tie2 signaling pathway. The therapeutics will constitute a potential adjunct treatment against coronavirus. The collaborative endeavor seeks to augment the survival rate of patients by lowering endothelial dysfunction and severity of infectious diseases, facilitated by an enhancement of host-directed therapeutic response. Early research is underway in the US and Canada.
Key Development Milestones
As at February 2020, early research for the treatment of COVID-2019 infections and other infections, was underway in the US and Canada  .
In April 2020, Q BioMed entered into a financial restructuring and received additional $US4 000 000. The company intends to use this funding to advance pipeline assets including a potential treatment for COVID-19, influenza and others, liver cancer therapy Uttroside B and rare disease drug development in non-verbal autism spectrum disorders  .
In February 2020, Q BioMed reported the submission of a funding application by Mannin, to the Small Business Technology Transfer Grant administered by the U.S. National Institutes of Health, for the investigation of specific applications of Mannin's therapeutic platform  .
In September 2019, Mannin became the recipient of a grant totaling approximately $US7.7 million, awarded by the German state of Saxony. The grant is intended for the advancement of Mannin's novel therapeutics, responsible for lowering endothelial dysfunction and loss of endothelial barrier integrity, implicated in viral and bacterial infections, leading to acute and severe lung injury  .